Axsome Therapeutics (AXSM) Capital Expenditures (QoQ) (2015 - 2026)
Axsome Therapeutics (AXSM) Capital Expenditures (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 12.36 Bn | 12.05 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.42% |
| Dec 31, 2025 | 22.41% |
| Sep 30, 2025 | 346.15% |
| Jun 30, 2025 | -96.15% |
| Mar 31, 2025 | 1,026.67% |
| Dec 31, 2024 | -66.67% |
| Sep 30, 2024 | 73.08% |
| Jun 30, 2024 | -46.94% |
| Mar 31, 2024 | 1,300.00% |
| Dec 31, 2023 | -98.11% |
| Sep 30, 2023 | 178.95% |
| Jun 30, 2023 | 87.32% |
| Mar 31, 2023 | -60.77% |
| Dec 31, 2022 | 174.24% |
| Sep 30, 2022 | -72.61% |
| Jun 30, 2022 | 12.62% |
| Mar 31, 2022 | 47,350.11% |
| Dec 31, 2021 | -99.83% |
| Sep 30, 2021 | 1,270.33% |
| Jun 30, 2021 | -37.07% |